Cove Private Wealth LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cove Private Wealth LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 440 shares of the biopharmaceutical company’s stock, valued at approximately $313,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp lifted its position in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares during the period. International Assets Investment Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after buying an additional 11,499 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Regeneron Pharmaceuticals by 0.7% during the second quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock worth $357,945,000 after acquiring an additional 2,270 shares during the period. Finally, Swiss National Bank raised its position in Regeneron Pharmaceuticals by 0.6% in the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock worth $338,079,000 after acquiring an additional 2,000 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on REGN shares. Barclays decreased their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Bank of America reiterated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Finally, Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ REGN opened at $681.58 on Monday. The firm’s 50 day moving average price is $738.60 and its 200 day moving average price is $949.32. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market cap of $74.90 billion, a P/E ratio of 16.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.